Emerging Nanotechnology Advances: Liposomal Formulations to Treat Non-Small Cell Lung Cancer: A Short Review
Gopika Ashokan, KB Sneed and Yashwant Pathak*
Published: December 19, 2022
Abstract
Lung cancer is one of the leading causes of death in the US and is caused mainly due to smoking. The number of patients that suffer from non-small cell lung cancer is around 85% of the total lung cancer population. Traditional treatment methods use radiation, chemotherapy, immunotherapy, surgery, and/or a combination to treat lung cancer. The issue with these traditional drugs is the non-specific toxicity caused at other healthy sites which causes side effects such as nausea, hair loss, etc. New advancements in science opened an avenue called nanodrug drug delivery system to make therapeutics 1-100 nm in size to increase bioavailability and specificity. In this review article, we discuss a promising nanodrug delivery system, liposomes, to target NSCLC for its treatment.
Keywords: Nanotechnology advances, Liposomes, Nano drug delivery systems, cancer cells, Abnormal cell growth, Lung cancer, Nanomedicine, Neo-adjuvant therapy